BioLineRx announced that hematopoietic stem cells (HSCs) mobilized by BL 8040 in combination with granulocyte colony-stimulating factor (G-CSF) were successfully...
BioLineRx announced that the Company has submitted its New Drug Application (NDA) to the FDA for BL 8040 (motixafortide) in stem cell mobilization (SCM) for autologous bone marrow transplantation for multiple myeloma patients.
Background: Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of chronic kidney disease (CKD) anemia.
Curemark, LLC announced that the Bl�m Study, a Phase III clinical trial to evaluate the safety and efficacy of CM-AT...
Venatorx Pharmaceuticals and Melinta Therapeutics announced that the FDA has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for cefepime-taniborbactam, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination antibiotic under review as a potential treatment for adult patients with complicated urinary tract infections (cUTI), including acute pyelonephritis caused by susceptible gram-negative microorganisms
Fabry disease (FD) is an X-linked lysosomal storage disorder resulting from the α-galactosidase A gene mutations. Enzyme-replacement-therapy (ERT) products for FD currently used include agalsidase alfa and agalsidase beta.
Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many cytotoxic chemotherapy regimens.
Objective: Trichotillomania (TTM) is associated with high rates of co-occurring depression and anxiety disorders. What the co-occurrence of TTM, depression or anxiety disorders means clinically and cognitively...
Knowledge of the involvement of the neurokinin substance P in emesis has led to the development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of chemotherapy-induced nausea and vomiting (CINV)...